BofA Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating
Amylyx Upgraded to Buy by BofA on Hypoglycemia Drug Potential
BofA Securities Upgrades Amylyx Pharmaceuticals(AMLX.US) to Buy Rating, Announces Target Price $10
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Amylyx Pharmaceuticals Inc (AMLX) and Intuitive Surgical (ISRG)
Neutral Stance on Amylyx Pharmaceuticals Amid Promising Data and Uncertainties
Leerink Partners Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating, Announces Target Price $4
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $8
Amylyx Pharma Analyst Ratings
Analysts' Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Amylyx Pharmaceuticals Inc (AMLX)
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating, Announces Target Price $3
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Taysha Gene Therapies (TSHA) and Lexeo Therapeutics, Inc. (LXEO)
Bank of America Securities Keeps Their Hold Rating on Amylyx Pharmaceuticals Inc (AMLX)
Buy Rating Affirmed for Amylyx Pharmaceuticals Amid Promising Drug Trials and FDA Breakthrough Designation
Balancing Potential and Uncertainty: Hold Rating on Amylyx Pharmaceuticals Post-Avexitide Acquisition
Analyst Ratings For Amylyx Pharma
Amylyx Pharma Analyst Ratings
Amylyx Pharmaceuticals: Holding Steady Amidst Expansion and Market Skepticism
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Centene (CNC) and Radnet (RDNT)
Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Teladoc (TDOC) and Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharma Analyst Ratings
No Data
No Data